Constructing PK Models



Similar documents
IV solutions may be given either as a bolus dose or infused slowly through a vein into the plasma at a constant or zero-order rate.

PHAR 7633 Chapter 19 Multi-Compartment Pharmacokinetic Models

Exercise Day 3-13 A PBPK Model for Methyl Mercury

1: CLINICAL PHARMACOKINETICS

Drug Excretion. Renal Drug Clearance. Drug Clearance and Half-Life. Glomerular Filtration II. Glomerular Filtration I. Drug Excretion and Clearance

QSAR. The following lecture has drawn many examples from the online lectures by H. Kubinyi

A Peak at PK An Introduction to Pharmacokinetics

PHAR 7633 Chapter 21 Non-Linear Pharmacokinetic Models

Absorption of Drugs. Transport of a drug from the GI tract

Volume of Distribution

DIVISION OF HUMAN NUTRITION

ORGAN SYSTEMS OF THE BODY

Lecture 3: Enzyme kinetics

Statistics and Pharmacokinetics in Clinical Pharmacology Studies

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética

Week 30. Water Balance and Minerals

Nursing 113. Pharmacology Principles

PRINCIPLES OF PHARMACOKINETICS

Page 1. Name: 1) Choose the disease that is most closely related to the given phrase. Questions 10 and 11 refer to the following:

Human Body Systems Project By Eva McLanahan

Lecture 11 Enzymes: Kinetics

NM- Nuclear Medicine

Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV

Pharmacology skills for drug discovery. Why is pharmacology important?

Guidance for Industry Safety Testing of Drug Metabolites

How To Understand Enzyme Kinetics

Equations for Primary FRCA

Name Class Date Laboratory Investigation 24A Chapter 24A: Human Skin

Human ADME and Studies with Radiolabeled Compounds: Phase I-IIa

North Bergen School District Benchmarks

Fexinidazole a new oral treatment for sleeping sickness update of development

Lab 18 The Digestive System

Biokinetic model of americium in the beagle dog. Salt Lake City, UT (U.S.A.)

BIO 137: CHAPTER 1 OBJECTIVES

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A

Ethyl Glucuronide. Where is the Drug? Detection Windows. Urine. Blood. Absorption and Distribution. Metabolism. Excretion

Medication Utilization. Understanding Potential Medication Problems of the Elderly

Exposure Modeling. Interpretation of biomonitoring data using physiologically based pharmacokinetic modeling. Centers for Human Health Assessment

Determinants of Blood Oxygen Content Instructor s Guide

Biological importance of metabolites. Safety and efficacy aspects

Section 4. Toxicology

Importance of water for weight loss

Gas Exchange Graphics are used with permission of: adam.com ( Benjamin Cummings Publishing Co (

THE HUMAN BODY SYSTEMS

Endocrine Glands and the General Principles of Hormone Action

Teriflunomide is the active metabolite of Leflunomide, a drug employed since 1994 for the treatment of rheumatoid arthritis (Baselt, 2011).

ENZYMES - EXTRA QUESTIONS

BIOAVAILABILITY & BIOEQUIVALENCE TRIALS

Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method

Functions of Blood System. Blood Cells

By Casey Schmidt and Wendy Ford

Interpretation of Data (IOD) Score Range

DIVISION OF HUMAN NUTRITION

Insulin kinetics during HyperInsulinemia Euglycemia Therapy (HIET)

CLOSED LOOP MODEL FOR GLUCOSE INSULIN REGULATION SYSTEM USING LABVIEW

Gas Exchange. Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (

Acid/Base Homeostasis (Part 4)

Digestion, Absorption. How & where?

Guidance for Industry

PHAR 7633 Chapter 22 Non-Linear Regression Analysis of Pharmacokinetic Data Individual Data and Population Analysis

NUCLEAR MEDICINE TECHNOLOGY CERTIFICATE APPLICATION INSTRUCTIONS

D. Vitamin D. 1. Two main forms; vitamin D2 and D3

Altitude. Thermoregulation & Extreme Environments. The Stress of Altitude. Reduced PO 2. O 2 Transport Cascade. Oxygen loading at altitude:

Chapter 48. Nutrients in Food. Carbohydrates, Proteins, and Lipids. Carbohydrates, Proteins, and Lipids, continued

Name Date Period. Keystone Review Enzymes

Dynamic Process Modeling. Process Dynamics and Control

Essentials of Human Anatomy & Physiology. 7 th edition Marieb, Elaine, Chapters Lab Manual, 2 nd edition and coloring book, 7 th edition

Enzymes. A. a lipid B. a protein C. a carbohydrate D. a mineral

Chapter 12. Temperature Regulation. Temperature Regulation. Heat Balance. An Overview of Heat Balance. Temperature Regulation. Temperature Regulation

Fourth Grade The Human Body: The Respiratory System Assessment

Testosterone Therapy for Women

How To Remove A Drug By Therapeutic Apheresis

Vascular System The heart can be thought of 2 separate pumps from the right ventricle, blood is pumped at a low pressure to the lungs and then back

Anatomy & Physiology Bio 2401 Lecture. Instructor: Daryl Beatty Day 1 Intro to Lecture 1

Reaction of Blue Food Dye with Bleach

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

Basic Pharmacology by Paul Nicolazzo the Wilderness Medicine Training Center wildmedcenter.com

Population Pharmacokinetics and Pharmacodynamics of Cisplatinum During Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure

ANSWERS AND MARK SCHEMES. (a) A - liver; 1 B -brain; 1 C - heart; 1 D - lung; 1 E - kidney; 1. (b) (i) E/kidney; 1. (ii) C/heart; 1.

The Rate and Extent of Calcium Bioavailability from Two Oral Dosage Forms in Rats

Water Homeostasis. Graphics are used with permission of: Pearson Education Inc., publishing as Benjamin Cummings (

5. Secretion: release of water, acids. Enzymes, buffers by digestive tract.

Carl Rosow, M.D., Ph.D. 1 HST-151. Lecture 1 - Principles of Pharmacology: Introduction

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS

DiNP Dose-Response Studies:

Introduction. MassDEP, Office of Research and Standards 1 Tetrachloroethylene

PKPD modelling of the relationship between testosterone and PSA in patients with prostate cancer during treatment with leuprorelin

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN

B.27. SUB-CHRONIC ORAL TOXICITY TEST REPEATED DOSE 90 - DAY ORAL TOXICITY STUDY IN NON-RODENTS

Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction

Paramedic Program Anatomy and Physiology Study Guide

Topic 3.0 Healthy human function depends on a variety of interacting and reacting systems

DOSE-EFFECT RELATIONSHIP

Fluid, Electrolyte & ph Balance

SWAT INPUT DATA:.GW CHAPTER 24

Ventilation Perfusion Relationships

Read-across and alternative testing strategies for REACH 2018

5.7 CHLOROTHALONIL (081)

Transcription:

Constructing PK Models Interpretation of biomonitoring data using physiologically based pharmacokinetic modeling Center for Human Health Assessment September 25-29, 29, 2006

Pharmacokinetics Studies of the change in chemical/metabolite distribution over time in the body Explores the quantitative relationship between Absorption, Distribution, Metabolism, and Excretion Classical Compartmental models - Data-based, empirical compartments - Describes movement of chemicals with fitted rate constants Physiologically-based models: - Compartments are based on real tissue volumes - Mechanistically based description of chemical movement using tissue blood flow and simulated in vivo transport processes.

Approaches to Pharmacokinetic Modeling Non-compartmental - Data summarization Compartmental - Statistical analysis -Interpolation Physiologically Based - Integration of Diverse Data -Extrapolation

Example of Simple Kinetic Model: One-compartment model with bolus dose Dose Volume? Purpose: In a 1-compartment 1 model, determine volume of distribution Terminology: Compartment = a theoretical volume for chemical Steady-state = no net change of concentration Bolus dose = instantaneous input into compartment Method: 1. Dose: Add known amount (A) of chemical 2. Experiment: Measure concentration of chemical (C) in compartment 3. Calculate: A compartmental Volume (V)

One-compartment model with bolus dose Basic assumption: - Well stirred, instant equal distribution within entire compartment Volume of distribution = A/C - In this model, V is an operational volume - V depends on site of measurement This simple calculation only works IF: - Compound is rapidly and uniformly distributed - The amount of chemical is known - The concentration of the solution is known. What happens if the chemical is able to leave the container?

Describing the Rates of Chemical Processes - 1 Chemical in the System Rate equations: - Describe movement of chemical between compartments The previous example had instantaneous dosing Now, we need to describe the rate of loss from the compartment by movement out of compartments or by loss due to metabolism within the compartment Zero-order process: - rate is constant, does not depend on chemical concentration rate = k x C 0 = k First-order process: - rate is proportional to concentration of ONE chemical rate = k x C 1

Describing the Rates of Chemical Processes - 2 Chemical Systems Second-order process: - rate is proportional to concentration of both of the chemicals Rate = k x C 1 x C 2 Saturable processes*: - Rate is dependent on interaction of two chemicals M-M kinetics - One reactant, the enzyme, is constant - Described using Michaelis-Menten* equation Rate = (V max x C) / ( C + K m ) 10 * Michaelis-Menten kinetics can describe: -Metabolism - Carrier-mediated transport across membranes -Excretion Rate 5 0 0 5 10 15 20 25 C

1-Comp model with bolus dose and 1 st order elimination Dose Conc? Concentration; Purpose: Examine how concentration changes with time Mass-balance equation (change in C over time): -da/dt=-k e x A, or dividing both sides by Vd -dc/dt=-k e x C where k e = elimination rate constant - Rearrange and integrate above rate equation C = C 0 x e -ke t, or ln C = ln C 0 -k e t Half-life (t 1/2 ): -Time to reduce concentration by 50% -replace C with C 0 /2 and solve for t t 1/2 = (ln 2)/k e = 0.693/k e

1-Comp model with bolus dose and 1 st order elimination Dose Conc Clearance: volume cleared per time unit - if k e = fraction of volume cleared per time unit, k e = CL/V (CL=ke ke*v) Calculating Clearance using Area Under the Curve (AUC): AUC = average concentration - integral of the concentration - C dt 10 CL = volume cleared over time (L/min) da/dt = - k e A = -k e V C da/dt = - CL C da = - CL C dt Dose = CL AUC CL = Dose / AUC Conc. 5 0 AUC 0 5 10 15 20 25 Time

1-Comp model with continuous infusion, 1st order elimination Calculating Clearance at Steady State - At steady state, there is no net change in concentration: dc/dt = k 0 /V k e C = 0 - Rearrange above equation: k 0 /V = k e C ss Steady State -Since CL = k e V, Conc. CL = k 0 /C ss Time

2-Comp model with bolus dose and 1 st order elimination k 12 1 2 Mass Balance Equations for Compartments k e k 21 Central Compartment (C1): dc1/dt = k 21 C 2 - k 12 C 1 - k e C 1 Peripheral (Deep) Compartment (C2): dc2/dt = k 12 C 1 - k 21 C 2 Conc. Time

Linear: Linear and Non-linear Kinetics All elimination and distribution kinetics are 1 st order -Double dose double concentration 100 Conc. 10 AUC 1 Non-linear: 0 5 10 15 20 25 Time At least one process is NOT 1 st order -No direct proportionality between dose and compartment concentration Dose 100 30 20 Conc. 10 Conc. 10 1 0 5 10 15 20 25 Time 0 0 5 10 15 20 25 Time

PBPK Models Building a PBPK Model: 1. Define model compartments Represent tissues 2. Write differential equation for each compartment 3. Assign parameter values to compartments Compartments have defined volumes, blood flows Venous side Chemical in air Lungs Other Fat tissues Liver Arterial side 4. Solve equations for concentration Numerical integration software (e.g. Berkeley Madonna, ACSL) Elimination Simple model for inhalation

Structuring PBPK Models What s needed and nothing more - Plausibility vs. Parsimony Considerations: -Uptake routes - Storage/sequestration/binding - Metabolism -Excretion - Target Tissue/Effect Compartment

Inhalation PBPK Model for Anesthetics C I Q P C X Q C Q C Lung C A C VL Q L Liver C VF Q F Fat C VR Q R Rapidly Perfused (brain, kidneys, etc.) C VS Q S Slowly Perfused (muscle, bone, etc.)

Compartments in a Physiological Model for Methylene Chloride QP CI QC CV Lung Gas Exchange QP CX Lung Tissue QC CA MFO GST QR CVR Richly Perfused Tissues QR CA QS CVS Slowly Perfused Tissues QS CA QF CVF Fat QF CA QL CVL MFO Liver GST QL CA Drink

Generic IV PBPK Model (Lutz and Dedrick) RBC Plasma Q pan Stomach Spleen Pancreas Gut Lumen Q f Muscle Fat Bone & Marrow Q int Skin & Fur Liver Q k Intestine Heart Kidneys Sex Organ Bladder Brain Prostate Thyroid Gonads

Models in Perspective no model can be said to be correct. The role of any model is to provide a framework for viewing known facts and to suggest experiments. -- Suresh Moolgavkar All models are wrong and some are useful. -- George Box

Approach for Developing a PBPK Model Problem Identification Mechanisms of Toxicity Literature Evaluation Biochemical Constants Physiological Constants Model Formulation Simulation Refine Model Compare to Kinetic Data Validate Model Design/Conduct Critical Experiments Extrapolation to Humans

Structuring the Model Tissue Grouping: 2 approaches Lumping: Tissues which are pharmacokinetically and toxicologically indistinguishable may be grouped together. Splitting: Tissues which are pharmacokinetically or toxicologically distinct must be separated.

Alternative Approaches for Selecting a PBPK Model Structure Lumping Splitting Body Body / Liver Rapid / Slow / Liver Rapid / Slow / Liver / Fat Only a Few Tissues Grouped All Tissues and Organs Separate

Splitting Compartments in a PBPK Model Tissue Rapidly Perfused (RP) Slowly Perfused (SP) Liver RP SP Fat Liver Lung RP SP Skin Fat Liver Lung Gut RP SP Skin W.Fat B.Fat

Structuring the Model Maintaining mass balance The sum of the tissue blood flows must equal the total cardiac output: ΣQ i = Q C Seems obvious? -- Perhaps, but frequently violated inadvertently in models, particularly when adding new tissue compartments or varying parameters -- e.g., when you split the skin compartment out of the slowly perfused tissue compartment, take its blood flow and volume out too!

Structuring the Model Tissue Grouping Criteria: perfusion rate = blood flow / volume R T =Q T / V T rapidly perfused: gut, liver, kidney, etc. slowly perfused: muscle, skin, fat rate constant (/hr) k T = Q T / (P T * V T ) P = C Tissue / C Blood where at equilibrium (e.g., distinguishes fat from the other slowly perfused tissues for a lipophilic compound)

Structuring the Model Tissue Grouping Considerations: Storage (e.g., blood cells) Excretion routes (e.g., hair) Flow-limited metabolism (e.g., liver) Uptake routes (e.g., skin) Target Tissues Distributional kinetics Note: the same decisions need to be made for each metabolite, valence, or conjugate formed

Building the Model Storage Compartments fat muscle liver kidney blood intestinal lumen

Typical Storage Tissue Compartment da T / dt = QT ( CA CVT ) assuming venous equilibration: C = C / VT Note: if V T is constant: T P T so: dat / dt = d( CT VT ) / dt = VT dct / dc / dt = Q ( C C / P ) / V T T A T T T dt

Blood compartment: da / dt = Σ( Q C / P ) Q B assuming steady state: therefore: B T T da B T T T / dt = 0 C = Σ( Q C / P ) / T Q C C C B

Building the Model Routes of Elimination liver (metabolism) kidney (urinary excretion) bile feces hair exhalation

Metabolizing Tissue (e.g., Liver): da L ( C C / P ) da / dt / dt = Q L A L L M where: da / dt = k C V / M and/or F L L P L (linear) max CL / PL / M + ( K C P ) V / L L (saturable)

RAL RAM RAO AL' = init CL init AL = 0.0 = CVL = QL = = ( CA CVL) ( VMAX CVL) /( KM CVL) KA MR RAL AL / VL = CL / PL AUCL' = CL PBPK modeling Conventions Ramseyan Code for the Liver AUCL = 0.0 RAM + + RAO + KF CVL VL In Berkeley Madonna, the differential equations have a different standard nomenclature: AL, AM, AO or dal/dt, dam/dt, dao/dt See Berkely Madonna User Guide.

Building the Model Distribution Perfusion (flow) limited Transport limited Diffusion limited Partitioning Binding

Transport Limited Kinetics VdC T ( CA ( C / P )), / dt = et QT T T where (0 < e T < 1) if e T = 1, kinetics is blood-flow (perfusion) limited

Diffusion Limited Kinetics Exchangeable compartment: E Diffusion limited compartment ( Q ( CA C )) ( PA ( C ( C P ))) VdC / dt = / I E ( C ( C P )) VdC / dt = PA / E I I E I I

Building the Model Uptake Routes inhalation drinking water oral gavage intravenous intraperitoneal Dermal Others (??)

Lung Equations for Inhalation Q P C X LUNG Air Spaces rapid equilibrium Q P C I Q C, C V dlung / dt = Capillary blood Q C, C A ( Q ( C C )) + ( Q ( C C )) C V A ( Q ( C C )) + ( Q ( C ( C P ))) dlung / dt = / A At equilibrium: C V A (( Q C ) + ( Q C ))/( Q + ( Q P )) C = / C V P I P C P C = C / At steady-state: dlung / dt = 0. 0 X A P B I I P A B X B

Uptake Routes Drinking water: da Oral gavage: ( Dose )/ 24. 0 k 0 = BW ( Q ( C ( C / P ))) ( k C ( V / P )) 0 / dt = k L L A L L F L L L + A St 0 da da St L = Dose BW / dt = k A A St ( Q ( C ( C / P ))) ( k C ( V P )) + ( k A ) / dt = / L A L L F L L L A St

Intravenous: A B 0 Uptake Routes or C = Q C +... + Q C + k / Q V where: k IV = Dose BW (( L VL ) ( F VF ) IV ) C ( Dose BW ) = 0.0, / t IV, t t < > t t IV IV

da da Sk SFC One-compartment Dermal Structure / dt = ( K (( ) )) P SA CSk / PSkL CSFC ( K SA ( C ( C / P ))) + ( Q ( C C / P )) / dt = P SFC Sk SkL Sk A Sk SkB IPA Acetone Schematic of the PBPK model for isopropanol and its metabolite acetone Designed for: - oral - inhalation -Dermal exposure routes CV CX QP CI*ff QC Lung QF Fat Surface P QSk Skin QR Rapid QS Slow QBr Brain QL Liver RAO VMaxC, KM CV CX QP Lung Fat Skin Rapid Slow Brain Liver CI QC QF QSk QR QS QBr QL VMax1, KM1 KAD KAS Duodenum KTSD Stomach PDOSE KTD

Building the Model Target Tissues -metabolism -binding - pharmacodynamics Metabolite Compartments - compartmental description - physiologically based description Experimental Apparatus -chamber -sampling device

Experimental Chamber Compartment C I Qv Chamber Qv C measured Cx N*Qp Cch Animals da Ch / dt = ( N Q ( C C )) + ( Q ( C C )) P Ch where N = the number of animals in the chamber, Q p = the single animal ventilation rate, Q V = the chamber air ventilation rate, C I = the chamber intake air concentration C X = the exhaled air concentration and C ch = the chamber concentration X V I Ch

Building the Model Other complications - Experimental problems Loss of material Preening - Total radioactivity data Represents sum of parent and metabolite concentrations May require other metabolites compartment - Tracer data If kinetics are dose-dependent, need to model both unlabeled and labeled material Similar problem for endogenous compounds - Multiple chemical interactions Competition Inhibition/induction

Observation: Co-exposure to TCE Decreases the Toxicity of 1,1-DCE 1,1-DCE alone 1,1-DCE plus TCE

Hypothesis: Metabolic Interaction

For inhibition of metabolism of compound B by compound T: Result: Gas Uptake Kinetic Analysis of 1,1-DCE / TCE Mixtures was Most Consistent with Competitive Inhibition

Predicted Inhibition of 1,1-DCE Metabolism by TCE (Assuming Competitive Inhibition)

Verification: The Toxicity of 1,1-DCE Is Proportional to the Predicted Amount of 1,1-DCE Metabolized, with or without Co-exposure to TCE

Linking Parent Compounds with Metabolites Human model for linear siloxane metabolites produced from metabolism of octamethylcyclotetrasiloxane. An initial metabolite distributes to a central compartment and is then metabolized to multiple downstream products.

Summary PBPK Model Development Scientific Method Analysis Observation (Literature) Observation (Literature) Hypothesis (Model Structure) Hypothesis (Model) Experimental Inference (Biology) Test (Experimental Data) Experimental Design (Simulation) Succeed Test (Literature Data) Fail Apply Tweak to Fit